{"disease":{"id":"relapsed-adult-all","name":"relapsed adult all"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06581081","title":"Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia","phase":"NA","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05679687","title":"ThisCART19A Bridging to alloHSCT for R/R B-ALL","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT03091933","title":"Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Ciusss de L'Est de l'Île de Montréal","has_results":false},{"nct_id":"NCT06287528","title":"A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04516551","title":"Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"Xinqiao Hospital of Chongqing","has_results":false},{"nct_id":"NCT03774654","title":"CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"Baylor College of Medicine","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}